- Home
- NXT vs JAZZ Comparison
NXT vs JAZZ Comparison
Compare NXT & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXT
- JAZZ
- Stock Information
- Founded
- NXT 2013
- JAZZ 2003
- Country
- NXT United States
- JAZZ Ireland
- Employees
- NXT N/A
- JAZZ N/A
- Industry
- NXT Semiconductors
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- NXT Technology
- JAZZ Health Care
- Exchange
- NXT Nasdaq
- JAZZ Nasdaq
- Market Cap
- NXT 6.5B
- JAZZ 6.1B
- IPO Year
- NXT 2023
- JAZZ 2007
- Fundamental
- Price
- NXT $46.54
- JAZZ $97.78
- Analyst Decision
- NXT Strong Buy
- JAZZ Strong Buy
- Analyst Count
- NXT 19
- JAZZ 13
- Target Price
- NXT $55.53
- JAZZ $181.85
- AVG Volume (30 Days)
- NXT 1.7M
- JAZZ 1.3M
- Earning Date
- NXT 05-14-2025
- JAZZ 05-06-2025
- Dividend Yield
- NXT N/A
- JAZZ N/A
- EPS Growth
- NXT 111.73
- JAZZ 49.21
- EPS
- NXT 3.48
- JAZZ 7.51
- Revenue
- NXT $2,771,370,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- NXT $15.93
- JAZZ $7.60
- Revenue Next Year
- NXT $11.04
- JAZZ $3.47
- P/E Ratio
- NXT $13.25
- JAZZ $13.00
- Revenue Growth
- NXT 21.46
- JAZZ 5.76
- 52 Week Low
- NXT $30.93
- JAZZ $95.49
- 52 Week High
- NXT $62.31
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- NXT 64.09
- JAZZ 33.01
- Support Level
- NXT $40.86
- JAZZ $97.50
- Resistance Level
- NXT $42.99
- JAZZ $120.67
- Average True Range (ATR)
- NXT 1.92
- JAZZ 4.33
- MACD
- NXT 0.59
- JAZZ -0.53
- Stochastic Oscillator
- NXT 96.40
- JAZZ 1.21
About NXT Nextracker Inc.
Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.